Janssen announces collaboration with Vertex on phase 2 study
5 November 2012 | By
To investigate an all-oral regimen of simeprevir (Tmc435) and Vx-135 for treatment of hepatitis C...
List view / Grid view
5 November 2012 | By
To investigate an all-oral regimen of simeprevir (Tmc435) and Vx-135 for treatment of hepatitis C...
18 May 2012 | By Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals announce results of an investigational Phase 3 study...
21 October 2011 | By Janssen Pharmaceuticals Inc.
New HIV data to be presented at EACS 2011...
29 August 2011 | By Janssen Pharmaceuticals, Inc.
NUCYNTA® ER approved for the management of moderate to severe chronic pain...
15 July 2011 | By Janssen Pharmaceuticals Inc
Janssen Pharmaceuticals, Inc. announced a definitive agreement to divest the assets of its Ortho Dermatologics division...